TRENDS IN PHARMACOEPIDEMIOLOGY OF RHEUMATOID ARTHRITIS
DOI:
https://doi.org/10.11603/2312-0967.2020.4.11540Keywords:
rheumatoid arthritis, pharmacotherapy, treatment schemesAbstract
The aim of the work. Comparative analysis of the pharmacotherapy of patients with rheumatoid arthritis (RA) in a health care institution and estimation of the impact of existing treatment protocol on the drugs prescribing.
Materials and Methods. The object of the study were medical cards and medical records of 89 and 108 inpatients with RA, who were treated in the Rheumatology Department of the City Clinical Hospital of Lviv No. 4 in 2009 and 2019 correspondingly. Methods of data retrieval, frequency, comparative, content analysis, data aggregation and cluster analysis were used.
Results and Discussion. Content analysis of medical records revealed that three groups of drugs were used for the pharmacotherapy of RA. They were disease-modifying antirheumatic drugs (DMARDs), glucocorticosteroids (GCS) and nonsteroidal anti-inflammatory drugs (NSAIDs). During the analysed period, the share of DMARDs prescribing significantly increased and the share of NSAIDs indications decreased. Comparative analysis of the schemes of pharmacotherapy of patients with RA allowed establishing an increase in the share of prescribing of those treatment schemes that use DMARDs, which meets the requirements of the current clinical protocol of medical care for patients with RA. Based on the cluster analysis of 24 international non-proprietary names of drugs, three groups of them were identified according to the frequency of their prescribing. To the first group belonged drugs that were not prescribed in 2019. The second and third groups included drugs – leaders and drugs with medium and low level of prescribing correspondingly.
Conclusions. The analysis of prescribed DMARDs, GCS and NSAIDs for RA pharmacotherapy showed a significant influence of clinical protocols on the choice of RA treatment tactics. Cluster analysis allowed dividing drugs into groups and identifying the most perspective drugs for the RA treatment.
References
Ponyk RM, Korytko ZI. [Disease and peculiarities of rehabilitation of patients with rheumatoid arthritis in the present time]. Zdobut. kiln. i eksperym. med. 2019;3:183-7. Ukrainian.
Bakalets NF, Nykyforova OP. [Analytical assessment of out-patient treatment of patients with rheumatoid arthritis]. Problemy zdorovya i ekologii. 2016;4(50). Available from: https://cyberleninka.ru/article/n/analiticheskaya-otsenka-ambulatornogo-lecheniya-patsientov-s-revmatoidnym-artritom/viewer. Russian.
Okonenko TY, Khrutskyy AK, Okonenko LB, Yvanova AV. [Analysis of the total product line of medicines used to treat progressive rheumatoid arthritis and its complications in hospital]. Vestnyk NovGU. 2016;6(97):95-9. Russian.
Okonenko TY, Khrutskiy AK, Ehorova ES. [Morbidity Novgorod region rheumatoid arthritis, an analysis of the basic treatment and information preferences]. Health and Education Millennium. 2016. Available from: https://cyberleninka.ru/article/n/zabolevaemost-naseleniya-novgorodskoy-oblasti-revmatoidnym-artritom-i-analiz-bazisnoy-terapii/viewer. Russian.
Chichasova NV. [Rheumatoid arthritis: problems of treatment at the present stage]. Sovremennaya revmatologiya. 2018;4:65-70. Russian.
Zinchuk YYu. Optimization of medical care of patients with rheumatoid arthritis based on pharmacoeconomic research. Extended abstract of Candidate’s thesis: 14.04.03. Moscow; 2013. 24 p. Russian.
Rudyuk LI, Kharitonova OM. [Pharmacotherapy of rheumatoid arthritis: a modern approach to the problem]. Ukr revmatol zhur. 2013;4:46-9. Ukrainian.
Kyrychenko OM, Hyzhka YeI. The assessment of compliance of the inpatient stage pharmacotherapy when treating rheumatoid arthritis with provisions of industry standards. Clinical pharmacy. 2016;20:38-41. DOI: 10.24959/cphj.16.1389.
Yakovlyeva LV, Titova AA. [Research of medicinal products of the NSAID of the pharmaceutical market in Ukraine for the period 2014–2018]. Farmatsev. zhurnal. 2019;4:41-51. Ukrainian. DOI: 10.32352/0367-3057.4.19.05
PostoyVV, Vyshnevska LI. The marketing research of the Ukrainian market of drugs for the treatment of arthritis. Visnyk farmatsii. 2018;1(93):38-42. DOI: 10.24959/cphj.16.1389.
Herbolka-Khanyk NL, Levytska OR. [Analysis of use of main drugs for treatment of patients with rheumatoid arthritis]. Ukr med almanakh. 2011;4:58-60. Ukrainian.
Herbolka-Khanyk NL, Hrushkovska DT, Borushevska LV. Comparative analysis of the assortment of the main drugs used for rheumatoid arthritis treatment in Ukraine and Great Britain. Ukr med almanakh. 2011;5:47-9. Ukrainian.
On approval of protocols for the provision of medical care in the specialty "Rheumatology". Order of the Ministry of Health of Ukraine dated 13.10.2006 № 676. Ukrainian. Avaialbel from: https://zakon.rada.gov.ua/rada/show/v0676282-06/ed20061012#Text.
Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care and medical rehabilitation for rheumatoid arthritis. Order of the Ministry of Health of Ukraine dated 11.04.2014 No. 263. Available from: https://dec.gov.ua/wp-content/uploads/images/dodatki/2014_263_revmat_artryt/2014_263_YKPMD_RA.pdf. Ukrainian.
Khanyk NL. [Organizational and economic substantiation of optimal medicamentous provision of population with non-steroidal anti-inflammatory drugs]. Extended abstract of Candidate’s thesis: 15.00.01. Lviv; 2009. 22p. Ukrainian.
List of new generation drugs for the treatment of rheumatoid arthritis. Detailed characteristics of representatives. Available from: https://sustav.med-ru.net/lechenie_sustavov/preparaty/spisok-p-novogo-pokoleniya-dlya-l-. Russian.
Bezhcheyko V. [Comparison of effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs)]. 2017;2(3):1-3. Available from: https://uk.e-medjournal.com/index.php/psp/article/view/48/107. Ukrainian.
Shuba NM, Voronova TD, Kokunov YuO. [Risks of NSAIDS and safe therapy selection]. Ukr revmatol zhur. 2018;1(71):16-22. Ukrainian.
Yaremenko OB, Ivashkovskyi OI, Fedkov DL. [The efficacy and tolerability of immunobiologic therapy in patients with rheumatoid arthritis] Ukr. revmatol. zhur. 2011. [Internet]. Available from: https://www.rheumatology.kiev.ua/wp/wp-content/uploads/2011/12/709.pdf?upload=. Ukrainian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Pharmaceutical Review
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
